Pearl Therapeutics Revenue and Competitors

Morristown, NJ USA

Location

$255.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Pearl Therapeutics's estimated annual revenue is currently $4.4M per year.(i)
  • Pearl Therapeutics's estimated revenue per employee is $100,500
  • Pearl Therapeutics's total funding is $255.5M.

Employee Data

  • Pearl Therapeutics has 44 Employees.(i)
  • Pearl Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.6M280%N/AN/A
#2
$7.2M36-8%N/AN/A
#3
$4180M133206%$550MN/A
#4
$9.4M4742%N/AN/A
#5
$6.7M119-37%$199.6MN/A
#6
$8M40-56%N/AN/A
#7
$9.2M4628%N/AN/A
#8
$106.3M52916%N/AN/A
#9
$11.9M5916%N/AN/A
#10
$48.2M24014%N/AN/A
Add Company

Pearl Therapeutics is developing a pipeline of advanced respiratory products that will offer patients and their healthcare providers a choice of formulations and dosage strengths better suited to their needs. Pearl's products will afford multiple health benefits compared to current treatment options and will be available in familiar and widely used dosage forms to enhance compliance. The company has licensed advanced particle technology from Nektar Therapeutics and is developing it further for application in selected fields.

keywords:N/A

$255.5M

Total Funding

44

Number of Employees

$4.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pearl Therapeutics News

2022-04-20 - Injectable Drug Delivery Devices Market Size, Scope And ...

... Novo Nordik, Sanofi, Unilife Corporation, Zogenix, Hospira, Presage Bioscience, MicroCHIPS, Pearl Therapeutics, Genentech, Bend Research.

2022-03-22 - Underscoring the Diversity Issue in Dermatology: Clinical ...

... in Dermatology: Clinical Trials, Therapeutics, and Care Management ... diversity representation was again referenced by Pearl E. Grimes,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.5M44-17%N/A
#2
$6.2M4419%N/A
#3
$9.5M4410%N/A
#4
$11.9M4525%N/A
#5
$35M4610%N/A